Abstract
Simple SummaryStereotactic radiation therapy (SBRT) is a type of radiation therapy in which a small number of high doses of radiation are delivered to a target volume using highly accurate equipment in order to maximize cancer control while minimizing side effects on healthy tissues. SBRT’s precise role varies according to the primary location and subtype of the oligometastatic state. The purpose of this review is to clarify the role of SBRT in various cancer types and to define its position based on the oligometastatic disease state.Stereotactic body radiation therapy (SBRT) is a form of radiation therapy (RT) in which a small number of high doses of radiation are delivered to a target volume using highly sophisticated equipment. Stereotactic body radiation therapy is crucial in two cancer stages: early primary cancer and oligometastatic disease, with the goal of inducing complete cancer remission in both. This treatment method is commonly used to treat a variety of disease types. Over the years, a growing body of clinical evidence on the use of SBRT for the treatment of primary and metastatic tumors has accumulated, with efficacy and safety demonstrated in randomized clinical trials. This article will review the technical and clinical aspects of SBRT according to disease type and clinical indication.
Highlights
Accepted: 22 February 2022Hellman and Weichselbaum first proposed the concept of oligometastatic disease in1995 [1]
Stereotactic body radiation therapy is a type of radiation therapy that involves delivering a small number of high doses of radiation to a target volume; this technique has quickly gained popularity due to its excellent tolerability and high loco-regional control rates that approach 90%
Evidence for treating oligometastasis is based on the proof-of-concept results of the SABR- COMET randomized trial, which demonstrated a significant increase in OS
Summary
Accepted: 22 February 2022Hellman and Weichselbaum first proposed the concept of oligometastatic disease in1995 [1]. Hellman and Weichselbaum first proposed the concept of oligometastatic disease in. An oligometastatic disease is a stage of the disease that is intermediate between locoregionally advanced and metastatic disease and is still treatable curatively. Oligo-recurrence, oligo-progression and oligo-persistence are the four categories of oligometastatic disease, corresponding to the different clinical scenarios that capture the spectrum of oligometastatic disease [2,3]. Oligometastasis refers to newly diagnosed cancer with few metastases occurring concurrently with the primary tumor. Oligo-recurrence refers to patients who have been treated for metastatic disease and have a relapse in a few new metastatic sites. Oligo-progression refers to patients who are controlled by systemic treatments and progress only on a few metastatic sites, whereas oligo-persistence refers to patients who respond to systemic treatment but still have a few metastatic sites
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
